Liquidia Corporation (LQDA)
NASDAQ: LQDA · Real-Time Price · USD
45.06
+0.07 (0.16%)
At close: Oct 30, 2026, 4:00 PM EDT
45.64
+0.58 (1.29%)
After-hours: Oct 30, 2026, 7:58 PM EDT
Liquidia Revenue
Liquidia had revenue of $171.68M in the quarter ending June 30, 2026, with 1,842.73% growth. This brings the company's total for the last twelve months to $450.91M, up 2,233.65% year-over-year. In the year 2025, Liquidia had annual revenue of $158.32M with 1,031.18% growth. That makes Liquidia the 11,846th largest company in the world by revenue and 2,351st in the United States.
Revenue (ttm)
$450.91M
Revenue Growth
+2,233.65%
P/S Ratio
8.94
Revenue / Employee
$2,087,532
Employees
216
Market Cap
4.03B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 158.32M | 144.32M | 1,031.18% |
| Dec 31, 2024 | 14.00M | -3.49M | -19.97% |
| Dec 31, 2023 | 17.49M | 1.55M | 9.75% |
| Dec 31, 2022 | 15.94M | 3.08M | 23.98% |
| Dec 31, 2021 | 12.85M | 12.11M | 1,637.77% |
| Dec 31, 2020 | 739.63K | -7.33M | -90.84% |
| Dec 31, 2019 | 8.07M | 5.37M | 198.20% |
| Dec 31, 2018 | 2.71M | -4.55M | -62.70% |
| Dec 31, 2017 | 7.26M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 11.11B |
| Perrigo Company | 4.14B |
| Hims & Hers Health | 2.58B |
| Lantheus Holdings | 1.56B |
| Indivior Pharmaceuticals | 1.37B |
| Prestige Consumer Healthcare | 1.10B |
| Kiniksa Pharmaceuticals International, | 945.96M |
| Supernus Pharmaceuticals | 865.11M |
LQDA News
- 17 days ago - Liquidia price target raised to $42 from $38 at BofA - TheFly
- 17 days ago - Liquidia price target raised to $65 from $58 at H.C. Wainwright - TheFly
- 18 days ago - Liquidia rises 25.3% - TheFly
- 18 days ago - Liquidia rises 29.1% - TheFly
- 18 days ago - This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario. - Barrons
- 18 days ago - LifeSci upgrades Liquidia to Buy on overhang clearing settlement - TheFly
- 18 days ago - Liquidia upgraded to Outperform from Market Perform at LifeSci Capital - TheFly
- 18 days ago - Liquidia price target lowered to $58 from $72 at Needham - TheFly